Intuitive Surgical shows no slowing
This article was originally published in The Gray Sheet
Executive Summary
Growth of robotic surgery systems firm continues to soar with second quarter sales of $87 mil., up 65% from the prior-year period, driven by strong performance from Intuitive Surgical's gynecologic sector, which became its second largest surgical segment. Hysterectomy was the fastest growing procedure, VP-Business Development & Strategic Planning Aleks Cukic noted during firm's Q2 earnings call July 26. The largest gainer two years running on "The Gray Sheet" OTC index, Intuitive shipped 39 of its million-dollar-plus da Vinci systems during the quarter, bringing the number of worldwide installations to 467 (1"The Gray Sheet" Jan. 23, 2006, p. 13)...
You may also be interested in...
NuVasive Boosts Artificial Disc Development, Stock; OTC Index Rises 15%
NuVasive will use profits gained from a series of 510(k)-cleared spinal devices to fuel artificial disc and nucleus replacement development in 2006
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.